story of the week
Intranasal Dihydroergotamine Mesylate for Acute Migraine Treatment
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Headache
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
STOP 301: A Phase 3, Open-Label Study of Safety, Tolerability, and Exploratory Efficacy of INP104, Precision Olfactory Delivery (POD® ) of Dihydroergotamine Mesylate, Over 24/52 Weeks in Acute Treatment of Migraine Attacks in Adult Patients
Headache 2021 Aug 07;[EPub Ahead of Print], TR Smith, P Winner, SK Aurora, M Jeleva, J Hocevar-Trnka, SB ShrewsburyFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.